United States Food and Drug Administration (USFDA) has completed a Post-marketing Adverse Drug Experience (PADE) inspection at Lupin’s global pharmacovigilance group. The inspection closed with no observations.
The inspection was conducted at Lupin’s global pharmacovigilance group based out of Mumbai from March 20 to March 24, 2023. The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |